Vivos (RDGL) Short term Debt (2011 - 2023)

Vivos' (RDGL) quarterly Short term Debt came in at $10000.0 in Q3 2023, down 99.97% quarter-over-quarter from $30.1 million in Q3 2018.

Vivos (RDGL) Short term Debt (2011 - 2023) Analysis & Trends

Vivos has disclosed Short term Debt across 9 years of filings, most recently posting $10000.0 for Q3 2023.

Short term Debt for Q3 2023 came in at $10000.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2023 was $10000.0 (changed N/A YoY), and the FY2016 annual result was $324532.0, down 92.34% from the prior year.
Short term Debt came in at $10000.0 for Q3 2023 at Vivos, down from $30.1 million in the prior quarter.
In the past five years, Short term Debt ranged from a high of $10000.0 in Q3 2023 to a low of $10000.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn
10	Vivos	-	-	-3,105.00

Download Data